Who We Are
At Emmes Group, our work is driven by a simple but profound belief: truth matters. Since our founding in 1977, we’ve been committed to uncovering truth in clinical research - through scientific rigor, operational excellence, and deep collaboration with our clients and partners. That truth fuels better decisions, faster treatments, and more confident health outcomes.
For more than 45 years, Emmes has supported clinical trials across a wide range of therapeutic areas and geographies. Our global presence today is rooted in decades of meaningful partnerships and a consistent mission: to help bring better treatments to patients, faster.
How We Started
Emmes was founded in 1977 with a focus on biostatistics and public sector research, establishing a strong foundation as a scientific partner to the U.S. government - including the National Institutes of Health (NIH). Over time, we built an unmatched level of engagement across NIH Institutes and Centers, leading critical research initiatives that shaped public health and clinical trial best practices.
From the beginning, our business was designed to serve mission-driven programs - where scientific precision, regulatory rigor, and data transparency are essential to uncovering meaningful evidence. That early work with government sponsors became the springboard for our later expansion into commercial biopharma and global clinical research.
A Legacy of Public Health Impact
Emmes has played a leading role in addressing some of the world’s most urgent health challenges. Our teams have supported research on infectious diseases, blood disorders, and the opioid epidemic to name just a few areas. We continue to advance global health through partnerships with organizations like the Gates Foundation, PATH, and IAVI.
We’re also proud of our long-standing role in hematopoietic stem cell transplantation (HSCT) and ophthalmology research. We’ve helped develop the foundation for HSCT research since 2001. And we’ve helped lead landmark studies - including the AREDS and AREDS2 trials - that have shaped treatment guidelines and improved outcomes for patients with age-related eye diseases.
A New Era of Growth
In June 2022, Emmes entered a new phase through a strategic partnership with New Mountain Capital, a leading investment firm focused on building innovation-driven companies.
This partnership has accelerated our global expansion, strengthened our network of clinical research sites, and fueled a series of strategic acquisitions that extend both our therapeutic expertise and geographic reach.
Building the Future of Clinical Research
Today, Emmes Group stands at the intersection of science, operations, and innovation. With the launch of Veridix, our technology and AI business unit, and continued investment in proprietary platforms, digital endpoints, and decentralized trials, we are redefining what’s possible in clinical research.
What drives us hasn’t changed: a deep commitment to scientific integrity, operational excellence, and the pursuit of truth. It’s this passion that continues to guide our work—helping uncover evidence that brings clarity, confidence, and better outcomes to patients around the world.
